Where Wegovy and Ozempic prescriptions are coming from; why Genentech is weighing slow-walking a cancer therapy

A new analysis suggests telehealth companies could account for nearly half of all insurance claims for GLP-1 prescriptions in 2022.

August 10, 2023 Check out STAT+

Sponsored By

Adobe STAT+ | Where are patients getting their prescriptions for GLP-1 drugs like Wegovy and Ozempic? A new analysis suggests telehealth companies could account for many patients with insurance claims for GLP-1 prescriptions in 2022. By Katie Palmer STAT+ | Genentech weighs slow-walking ovarian cancer therapy to make more money under drug pricing reform Genentech is considering slow-walking an ovarian cancer therapy to make more money under drug pricing reform. By Rachel Cohrs STAT+ | What to know about concerns raised about compounded versions of Novo Nordisk's Wegovy STAT explains what to know about concerns raised about compounded versions of Novo Nordisk's Wegovy and Ozempic. By Ed Silverman Courtesy Anne Adams/UCSF Memory and Aging Center How a beautiful symptom of a brutal dementia informs our understanding of creativity A small percentage of people with frontotemporal dementia also experience an explosion of artistic creativity. By Bree Iskandar STAT+ | AdventHealth sues MultiPlan, alleging a 'cartel' that underpays out-of-network medical claims AdventHealth is suing MultiPlan, alleging the company has worked with health insurers to create a "cartel" to underpay out-of-network claims. By Bob Herman STAT+ | Anavex, maker of rare disease drug, keeps shifting the goalposts in its clinical trials If Anavex's drug fails to achieve the pre-determined goals, the thinking apparently goes, just make a post-hoc change to the study goals. By Adam Feuerstein Listen: Your guide to Wegovy's blockbuster heart study In the wake of a big trial of Novo Nordisk's obesity drug Wegovy, STAT's Elaine Chen joins us to explain what we know and don't know. By Damian Garde and Allison DeAngelis and Adam Feuerstein STAT+ | A yogurt drink instead of a colonoscopy? Study uses engineered bacteria to detect cancer A proof-of-concept study shows that DNA-slurping bacteria can identify cancerous sequences, advancing hope of a gentler form of diagnostics. By Angus Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser